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Low vitamin D and insufficient sun exposure are additive independent risk factors for the 
development of multiple sclerosis (MS). The usual measure of vitamin D status, serum 
25-hydroxy vitamin D [25(OH)D], is also a marker of recent exposure to the UVB rays of 
sunshine. The main evidence for a protective effect for MS development of higher 25(OH)
D comes from observational studies, but this study design cannot separate out whether 
25(OH)D is acting as a marker of vitamin D status, sun exposure, or both. In light of a 
lack of definitive outcomes in MS patients after trials of vitamin D supplementation and 
the ability of narrowband UVB to induce vitamin D, as well as other immune-regulatory 
molecules in skin, the Phototherapy for Clinically Isolated Syndrome (PhoCIS) trial was 
established to investigate the benefits of narrowband UVB, in addition to supplemented 
vitamin D, on MS development in individuals with Clinically Isolated Syndrome. We 
propose that the PhoCIS trial provides a fresh approach to re-defining the reported 
associations of 25(OH)D levels with MS development and progression.
Keywords: narrowband UVB phototherapy, vitamin d, multiple sclerosis, clinically isolated syndrome, UV-induced 
immunosuppression, trial, vitamin d supplementation
introdUCtion
Multiple sclerosis (MS) is a progressive currently incurable, immune-mediated disease of the central 
nervous system (CNS). Both genetic and environmental factors contribute to MS disease risk, largely 
through effects on immune pathways [reviewed in Ref. (1, 2)]. Increasing MS incidence, prevalence 
and mortality with increasing latitude, seasonal effects in relapse rates, and association of MS risk in 
observational studies with less past sun exposure (1) have led to a focus on insufficient vitamin D as 
a major risk factor. This was further supported by season of birth effects for MS risk (3). However, 
studies in humans and mice by us and others [reviewed in Ref. (4, 5)] suggest that immune regulation 
by UV radiation (UVR) is by both vitamin D-dependent and vitamin D-independent pathways. Our 
epidemiological work (6, 7) indicates that vitamin D and sun exposure are additive independent 
FigUre 1 | Flow chart of the study design for phototherapy for 
Clinically isolated syndrome. Participants are in the study for 12 months 
with half given narrowband UVB phototherapy. Blood is collected at the time 
of enrollment and after 7 days and 1, 2, 3, 6, and 12 months. Narrow band 
phototherapy is delivered three times per week for the first 8 weeks of their 
participation in the trial. Progression is monitored by MRIs after 3, 6, and 
12 months.
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risk factors for MS development. A Swedish study has supported 
these findings (8). Further, direct effects of sun exposure on MRI 
measures of neurodegeneration in MS, independently of vitamin 
D, have been reported (9). Thus, associations of 25(OH)D with 
MS disease progression cannot assume causality of vitamin D and 
the efficacy of supplementation in the MS disease process even if 
this is an effective way to raise 25(OH)D levels.
These findings suggest that multiple molecules, including 
vitamin D, produced in the skin in response to UVR exposure, 
may contribute to the latitude gradient in incidence, prevalence, 
and mortality of MS. The question then becomes which strategy 
might we use to reduce the incidence of MS? Should it be vitamin 
D supplementation (surely the easiest option with proven safety), 
or is UVB exposure preferable as it will stimulate the production 
of vitamin D as well as the multiple other immune-modifying 
molecules (see below). Here, we introduce the Phototherapy 
for Clinically Isolated Syndrome (PhoCIS) Trial, which was 
designed to give individuals at high risk of MS the benefits of 
both vitamin D and other molecules produced in UVR-exposed 
skin. Recruitment of participants is ongoing, but here we provide 
the background and justification for the trial.
tHe phoCis triaL
The PhoCIS trial examines the effects of narrow band UVB 
therapy on immune and inflammatory markers of disease, as 
well as MRI, in patients diagnosed with CIS within the last 
120 days (ACTRN12614000185662). The protocol has received 
approval from the University of Western Australia Human 
Research Ethics Committee (2014-02-083), and informed con-
sent has been obtained from each participant. All participants 
receive sufficient vitamin D supplementation to achieve serum 
25(OH)D levels of ≥80  nmol/L, as standard care. Half of the 
participants are randomized to receive the narrowband UVB 
phototherapy, in addition to vitamin D supplementation. The 
systemic immune-suppressing effect of UVR exposure has been 
extensively demonstrated in humans (10, 11). For example, a 
single sub-erythemal exposure of either 0.25 or 0.5 minimal 
erythemal dose (the dose of erythemally weighted UVR that 
causes a just perceptible reddening of the skin) of UVR sup-
pressed contact hypersensitivity responses by 50 and 80%, 
respectively, of volunteers with Fitzpatrick-defined human skin 
types I (always burns, never tans) and II (usually burns, tans 
with difficulty) (12, 13). Human and murine studies suggest a 
prominent role in UVR-induced immune suppression for den-
dritic cells (DCs) and induced T-regulatory and B-regulatory 
cells, culminating in reduced T and B cell responses [reviewed 
in Ref. (4, 5, 14)].
participants
We plan to recruit 60 participants, of which 30 will receive nar-
rowband UVB phototherapy. All participants in PhoCIS have 
been diagnosed with CIS, the first clinical presentation of a 
disease that shows characteristics of inflammatory demyelination 
that could be MS, but has yet to fulfill the criterion of progres-
sion in time, i.e., the participants have had only a single clinical 
episode (15). The primary end point is progression to MS, i.e., a 
second exacerbation defined by imaging (gadolinium-enhancing 
lesions or new or unequivocally enlarging T2 lesions) (16). CIS 
is recognized as a time when the disease course may be more 
susceptible to intervention resulting in deviation or slowing of 
disease development. Clinical trials of interferon beta-1a (17) or 
glatiramer acetate (18) have shown that individuals with CIS who 
receive treatment are less likely to develop a second exacerbation 
and have reduced MRI activity. In Australia, CIS patients are 
not eligible for disease-modifying therapy (DMT), which could 
complicate assessment of the modulating effects of narrow band 
UVB phototherapy.
intervention
The intervention is very similar to that given to patients with 
psoriasis where narrow band UVB phototherapy has proven safe 
and effective, with very minimal adverse side effects (19, 20). 
Standard phototherapy (UVB between wavelengths 311–312 nm) 
is given three times/week for 8  weeks (24 exposures in total). 
Phototherapy is delivered according to the Dundee protocol; a 
starting dose of 20 mJ/cm2 has been chosen based on knowledge 
of skin type and is well below the threshold for erythema for 
Fitzpatrick-defined skin types 1–II. All patients start with 40% 
increments on their initial dose, and this is reduced to 20% 
increments after six exposures. Using a similar protocol, narrow 
band UVB exposures were given three times/week for 4 weeks 
to 33 healthy adults with a mean (±SD) baseline of 25(OH)D of 
52.9 ± 10.4 nmol/L (21). Serum 25(OH)D levels increased by a 
mean of 41.0 nmol/L (95% CI 34.8–47.2) and support claims that 
narrow band UVB phototherapy will increase vitamin D status. 
For comparison, 25(OH)D levels increased by 20.2 nmol/L (95% 
CI 14.6–26.0) from a similar baseline in 30 individuals given 
20 µg (800 IU) oral cholecalciferol daily for 4 weeks (21).
assessment of disease progression
Participants are followed for 12 months, both clinically and with 
repeated MRI (assessed after 3, 6, and 12 months) (Figure 1) 
and with assay of standard immunological biomarkers in 
3Hart et al. Narrowband UVB Phototherapy for CIS
Frontiers in Immunology | www.frontiersin.org January 2017 | Volume 8 | Article 3
blood (beyond the scope of this paper). Blood is drawn by 
venepuncture at the time of enrollment and after the first week, 
first month, and second month (time of end of phototherapy for 
those receiving it). Blood is also drawn after 3, 6, and 12 months 
(Figure 1). We propose that due to the active exchange between 
blood and the CNS, assessments of the phenotype and func-
tion of blood cells will provide a window into changes at the 
site of the inflammatory, demyelinating lesions associated with 
development of MS.
The effects of narrowband UVB phototherapy have been 
previously investigated in nine patients with relapsing-remitting 
MS, i.e., a more established form of MS [mean time (±SEM) 
since diagnosis, 13  ±  8  years] (22). All but two participants 
were on DMT (interferon β 1a, natalizumab, glatiramer acetate). 
They were given sub-erythemal narrowband UVB phototherapy 
five times per week for 6  weeks and followed up by MRI and 
neurological testing for 6 months. Although there were no neu-
rological improvements, the participants felt much better. Serum 
levels of 25(OH)D increased over the 6 weeks from 35.0 ± 8.0 
to 103.7 ± 10.6 nmol/L (mean ± SEM, n = 9)(22). Those treated 
showed an increase in T-regulatory cells and IL-10-producing 
DCs in UV-irradiated skin and an elevated subset of T-regulatory 
cells in the blood. When CD4+ cells from the blood were re-
stimulated in vitro, they expressed less IL-21, which by its func-
tion may help to explain the increased T-regulatory cell numbers 
(23). The significance of these changes in individuals on DMT 
therapy is under investigation. In PhoCIS, the participants are 
DMT-free when recruited.
WHy estaBLisH phoCis WHiLe a triaL 
oF oraL VitaMin d sUppLeMentation 
WoULd Be easier?
Supplementation of patients with CIS with oral vitamin D would 
be simpler and easier to manage. With respect to prevention 
of MS, there have been two previous studies. The first was a 
randomized controlled trial in Iran of 30 optic neuritis patients 
given 50,000 IU vitamin D3 per week for 12 months (24). There 
were significantly fewer cases of a second demyelinating attack 
measured on MRI in the treated group. The second study was a 
retrospective case–control study in Norway of self-reported con-
sumption of cod liver oil (5 mL contains 400 IU vitamin D), during 
childhood, adolescence, and adulthood by MS adults diagnosed 
for <10 years (25). A significant reduction of risk for cod liver oil 
consumption was recorded only for intake during adolescence. 
Thus, there is some but limited evidence of a potential benefit of 
vitamin D supplementation for the prevention of MS and the two 
reported studies require verification. In Australia, the PrevANZ 
study is examining the effects of oral vitamin D supplementation 
on individuals with CIS with the end point of progression to MS 
by MRI criteria (ACTRN12612001160120). A similar trial has 
been established in France (D-Lay-MS, NCT01817166).
The majority of published studies have investigated the treat-
ment of MS with vitamin D; these were recently detailed in a 
Rapid Response Report by the Canadian Agency for Drugs and 
Technologies in Health (26). The authors evaluated the clinical 
effectiveness of vitamin D supplementation in four systematic 
reviews (27–30), eight randomized controlled trials (24, 31–37), 
and three non-randomized studies (25, 38, 39). The authors 
of the CADTH Rapid Report concluded that “the outcomes 
of vitamin D supplementation for MS were heterogeneous, 
conflicting and inconsistent, with no effect on disability scores 
and relapse rates. Further, there were both positive and negative 
results for immunologic factors, imaging studies, and functional 
outcomes.” Other studies suggest that ongoing inflammation, as 
in MS, may hinder systemic increases in 25(OH)D levels with 
supplementation (40).
proposed MeCHanisM oF 
preVention oF Ms deVeLopMent  
By UVB pHototHerapy: VitaMin 
d-dependent patHWays
The precursor of vitamin D in keratinocytes, 7-dehydrocho-
lesterol, absorbs UVB photons to initiate a pathway of vitamin 
D production, followed by hydroxylations in the liver, kidney, 
and immune and epithelial cells, and ultimately the biosyn-
thesis of 1,25-dihydroxy vitamin D [1,25(OH)2D], the active 
form of vitamin D (41). Unless supplemented, humans obtain 
up to 80% of their vitamin D by sun exposure. Many recent 
reviews have covered the immunomodulatory properties of 
1,25(OH)2D (42), particularly with reference to regulation of 
cells proposed important to the development of MS. Genetic 
variation of the Vitamin D regulating genes, CYP27B1 and 
CYP24A1, have also been identified as risk factors (2). Many 
of the properties of 1,25(OH)2D have been detected in  vitro 
with isolated cell populations and using concentrations of 
1,25(OH)2D that are much higher than systemic levels, includ-
ing pharmacological doses. However, immune cells have the 
enzymes to convert vitamin D or 25(OH)D to 1,25(OH)2D, 
and local concentrations, at the level of the cells, may be much 
higher than systemic levels (43). Generally, there is evidence 
that 1,25(OH)2D can stimulate the generation of tolerogenic 
DCs (44), and enhance both the number and function of 
T-regulatory cells (45). Direct effects on all immune cell types 
have been reported, which is supported by their expression of 
the vitamin D receptor. There are also many effects of vitamin 
D on human immune cells that are still not fully understood, 
particularly as responses by human and murine cells can vary. 
For example, 25(OH)2D can control T cell antigen receptor 
signaling and activation of human but not murine T cells (46). 
Furthermore, trials of vitamin D supplementation for multiple 
conditions have generally been disappointing (30, 47, 48) and 
have raised questions about the immunomodulatory abilities 
of vitamin D in vivo.
UV radiation-induced vitamin D may also regulate the devel-
opment of MS by its effects on VDR-expressing non-immune 
cells in the CNS. In one study of CIS patients, each 25 nmol/L 
increase in 25(OH)D level was significantly associated with 
7.8 mL higher gray matter volume, and there was a trend for an 
inverse relationship over 12  months between 25(OH)D levels 
and new brain lesions and clinical relapses (49). As vitamin D 
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maternal deficiency has been associated with altered development 
of multiple organs before birth (50), it is possible that vitamin D 
may positively regulate re-myelination programs.
proposed MeCHanisM oF 
preVention oF Ms deVeLopMent  
By UVB pHototHerapy: VitaMin 
d-independent patHWays
Several chromophores in skin for UVB photons have been impli-
cated in vitamin D-independent pathways: trans-urocanic acid 
in the stratum corneum, DNA, RNA, lipids and tryptophan of 
keratinocytes, and antigen-presenting cells [reviewed in Ref. (4, 
5, 10, 11)]. All may initiate pathways involved in signaling from 
skin to immune cells in draining lymph nodes and tissues beyond. 
It has been shown that T-regulatory cells are induced locally 
but then migrate to sites of inflammation, including the CNS, 
for regulation of experimental autoimmune encephalomyelitis 
(EAE), the murine model of MS (22). Epidermal Langerhans cells 
have been implicated in the immune regulation of narrowband 
UVB phototherapy (51). Importantly, sub-erythemal amounts of 
UVR, as in narrowband UV phototherapy, can suppress both local 
and systemic immunity, measured functionally by reduced cell-
mediated immune responses. A recent advance in understanding 
the immune regulation by sub-erythemal UVR has come from 
studies of keratinocyte-derived host defense peptides, previously 
called antimicrobial peptides. These peptides have modest anti-
microbial activity but rather pleiotropic immunoregulatory prop-
erties (52). They are produced in sub-erythemal UV-irradiated 
skin in the absence of any inflammation (53); they include 
cathelicidin LL-37 and the α- and β-defensins (52). As shown 
in a murine model, β-defensins via induction of T-regulatory 
cells can prevent and mitigate EAE (54). Recent studies have also 
implicated UVR in the maintenance of a pool of B-regulatory 
cells in the periphery that can prevent an autoimmune attack on 
the CNS (55). Narrow band UVB irradiation can also increase 
peripheral T-regulatory cell numbers and their suppressive func-
tion in patients with polymorphic light eruption (56).
Further advances to understanding the long-term effects of 
UVR exposure have come from studies of myeloid progenitors in 
the bone marrow of UV-irradiated mice (57–59). Immune cells 
in peripheral organs, including DCs that are the most important 
cells in initiating immunity, are constantly being replaced by 
bone marrow-derived hemopoietic cells. We have shown that 
a single irradiation of skin with erythemal UVR, or multiple 
sub-erythemal exposures, can suppress contact hypersensitivity 
responses at distant skin sites for between 1 and 3 months, and 
suggests bone marrow involvement per se (58, 60). Using chimeric 
mice engrafted with bone marrow from UV-irradiated mice, UV 
irradiation of skin alters the differentiation program of myeloid 
progenitors in bone marrow, so terminally differentiated DCs and 
macrophages are less immunogenic and more regulatory (58, 60). 
The reduced immunogenicity (confirmed in skin and airways) 
causes an attenuated ability of bone marrow-derived DCs to 
respond to inflammatory signals and associated antigens, and to 
prime new immune responses (58, 60). Adoptive transfer of DCs 
differentiated from the bone marrow of UV-irradiated mice and 
loaded in vitro with antigen can reduce inflammatory challenge 
responses in mice already sensitized to that antigen (58, 60), a 
scenario that can be likened to injected DCs suppressing ongoing 
autoimmune disease, such as MS. Importantly, the effect of sub-
erythemal UVR to skin on bone marrow myeloid progenitors is 
by a vitamin D-independent, prostaglandin E2 (PGE2)-dependent 
process (57), with an epigenetic modification of an early myeloid 
progenitor in the bone marrow proposed. Involvement of UVR, 
bone marrow-differentiated DCs, and PGE2 in MS pathogenesis 
is supported by the identification of the gene encoding PTGER4, 
a PGE2 receptor that is an intermediary for the UV effects on 
DC progenitors in the bone marrow, as an MS risk factor in 
genome-wide association studies (2). We propose that in patients 
with CIS, exposure to narrow band UVB will similarly alter the 
immunogenic properties of circulating DCs and their precursor 
cells toward a regulatory profile. As UVB exposure can simulate 
innate immunity (61), we do not anticipate detrimental effects 
of the narrowband UVB phototherapy on host responses to 
infection.
ConCLUsion
Association of lower 25(OH)D levels with increased risk of MS 
and greater relapse rate, and the plausibility of 1,25(OH)2D as a 
biochemical modulator of MS pathogenic processes, has encour-
aged multiple trials of vitamin D supplementation. However, the 
inconclusive outcomes to date of these trials encourage a fresh 
approach to re-interpret the reported associations. As 25(OH)D 
levels are generally a measure of recent sun exposure, we propose 
that the source of 25(OH)D on MS prevention is investigated. 
The PhoCIS trial has been established for individuals with CIS 
who are administered narrowband UVB phototherapy 24 times 
over 8 weeks and assessed neurologically and immunologically 
for 12  months. There are multiple immunomodulatory agents, 
in addition to vitamin D, produced in UVB-irradiated skin; we 
propose that by giving individuals at high risk of developing MS 
narrowband UVB phototherapy that they will gain the benefits of 
both vitamin D and other molecules implicated in UVB-induced 
immunoregulation.
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